Miami, FL, June 23, 2023 – Bodor Laboratories Inc., a privately held pharmaceutical research and development company, proudly announces the latest achievement of its sublicensee, Kaken Pharmaceutical Co. Ltd., in forging a partnership with Dong Wha Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company. This collaboration aims to market sofpironium bromide, a groundbreaking molecule discovered at Bodor Laboratories Inc., for the treatment of hyperhidrosis in Korea.

Dr. Nicholas Bodor, CEO and President of Bodor Laboratories Inc., expressed his satisfaction with the partnership, stating, “We are pleased with the continued success of Kaken Pharmaceutical in the further promotion of our molecule sofpironium bromide through their agreement with Dong Wha Pharmaceutical. Kaken’s impressive success in development and marketing of the molecule for hyperhidrosis (ECCLOCK®) in Japan positioned them well to partner with the prestigious Korean pharmaceutical company.”

Hyperhidrosis, a condition characterized by excessive sweating, affects millions of people worldwide and significantly impacts their quality of life. Sofpironium bromide, a result of Bodor Laboratories Inc.’s groundbreaking research, has shown immense potential in providing relief to those suffering from this debilitating condition. Through the partnership between Kaken Pharmaceutical and Dong Wha Pharmaceutical, this innovative treatment will now be made available to patients in Korea, ensuring improved healthcare options for individuals struggling with hyperhidrosis.
In addition to the success achieved in Korea, Bodor Laboratories Inc. remains optimistic about the progress of sofpironium bromide in the United States. The molecule is nearing market approval for the treatment of hyperhidrosis through the efforts of Botanix SB Inc., the licensee for Bodor Laboratories Inc.’s technology.
Dr. Nicholas Bodor highlighted the significant advancements in the United States, stating, “Our licensee for sofpironium bromide exclusively for hyperhidrosis, Botanix SB (a subsidiary of the Australian company Botanix Pharmaceuticals Co Ltd), has benefited immensely from the full clinical development of the drug by the previous licensee Fresh Tracks Therapeutics (formerly Brickell Biotech) and their continued support in guiding the NDA submission with the FDA. We look forward to the project’s likely approval this Fall and the subsequent marketing of the treatment by Botanix’s skilled team members.”
As Bodor Laboratories Inc. continues to witness the growing success and global adoption of sofpironium bromide, the company remains committed to advancing pharmaceutical research and development, with the ultimate goal of improving patients’ lives worldwide.